T2 Biosystems is a company that makes tests to help doctors find out if someone has an infection caused by a type of fungus called Candida. They want to make their test work for children too, so they asked the FDA (a group that checks if medicines and tests are safe) if it's okay to use their test on kids. People think this is good news, so the company's shares (pieces of the company that people can buy) are worth more today. Read from source...

1. The article is too short and lacks depth and details about the company's background, products, market position, competitors, challenges, opportunities, etc. It seems like a superficial and hasty piece of writing that does not provide any valuable insights for investors or readers.
2. The article uses vague and misleading terms such as "Zinger Key Points" without explaining what they are or why they matter. This creates confusion and suspicion among the audience who might wonder if the author is trying to manipulate or deceive them with these catchy phrases.
3. The article repeats information that was already mentioned in the previous paragraph, such as the name of the company, the product, and the FDA submission. This indicates a lack of coherence and structure in the writing, as well as an attempt to fill up space without adding any new or relevant content.
4. The article does not provide any sources, references, or evidence to support its claims or assertions about the company's performance, prospects, or benefits. This makes the article seem unreliable and biased, as well as lacking credibility and authority.

Positive

I have read and analyzed the article titled "Why In Vitro Diagnostics Company T2 Biosystems Shares Gaining Today". The main reason for the increase in share price is that the company submitted a 510(k) premarket notification to the FDA to expand the use of its T2Candida Panel to include pediatric testing. This panel can detect sepsis-causing Candida pathogens directly from blood, without waiting for positive blood culture results. The article presents this news as a positive development for the company and its shareholders, as it could potentially improve the diagnosis and treatment of candidemia in pediatric patients. Therefore, I would classify the sentiment of the article as positive.